Neutralizing antibodies against adeno-associated viruses in inflammatory bowel disease patients: Implications for gene therapy

Inflammatory Bowel Diseases

Volumn 17, Issue 12, 2011, Pages 2436-2442

  Van Der Marel, Sander ^a,b   Comijn, Elisabeth M ^a   Verspaget, Hein W ^b   Van Deventer, Sander ^a,b   Van Den Brink, Gijs R ^c   Petry, Harald ^a   Hommes, Daniel W ^b   Ferreira, Valerie ^a  

^a Amsterdam Molecular Therapeutics (AMT) BV   (Netherlands)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^c ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

antibodies; gene therapy; inflammatory bowel diseases; neutralizing

Indexed keywords

NEUTRALIZING ANTIBODY; PARVOVIRUS VECTOR;

ADENO ASSOCIATED VIRUS; ADOLESCENT; ADULT; AGED; ANTIBODY TITER; ARTICLE; BLOOD DONOR; BLOOD SAMPLING; CONTROLLED STUDY; CROHN DISEASE; ENTERITIS; FEMALE; GENE THERAPY; HUMAN; HUMAN CELL; HUMORAL IMMUNITY; MAJOR CLINICAL STUDY; MALE; PHENOTYPE; PRIORITY JOURNAL; SEROTYPE; ULCERATIVE COLITIS; VIRUS CAPSID; VIRUS NEUTRALIZATION;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; CASE-CONTROL STUDIES; COLITIS, ULCERATIVE; CROHN DISEASE; DEPENDOVIRUS; FEMALE; GENE THERAPY; GENETIC VECTORS; HUMANS; MALE; MIDDLE AGED; PROGNOSIS; YOUNG ADULT;

EID: 80455169793     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1002/ibd.21673     Document Type: Article

References (34)

1. Waterman M, Xu W, Stempak JM, et al. Distinct and overlapping genetic loci in Crohn's disease and ulcerative colitis: correlations with pathogenesis. Inflamm Bowel Dis. 2010 [Epub ahead of print].
2. Baumgart DC, Carding SR,. Inflammatory bowel disease: cause and immunobiology. Lancet. 2007; 369: 1627-1640. (Pubitemid 46722636)
3. Hanauer SB,. Inflammatory bowel disease: epidemiology, pathogenesis, and therapeutic opportunities. Inflamm Bowel Dis. 2006; 12 (suppl 1): S3-S9. (Pubitemid 43068428)
4. Cannom RR, Kaiser AM, Ault GT, et al. Inflammatory bowel disease in the United States from 1998 to 2005: has infliximab affected surgical rates? Am Surg. 2009; 75: 976-980.
5. Londei M, Quaratino S, Maiuri L,. Celiac disease: a model autoimmune disease with gene therapy applications. Gene Ther. 2003; 10: 835-843. (Pubitemid 36656628)
6. Prieto J, Herraiz M, Sangro B, et al. The promise of gene therapy in gastrointestinal and liver diseases. Gut. 2003; 52 (suppl 2): ii49-ii54. (Pubitemid 36523627)
7. Wirtz S, Neurath MF,. Gene transfer approaches for the treatment of inflammatory bowel disease. Gene Ther. 2003; 10: 854-860. (Pubitemid 36656630)
8. Aiuti A, Bachoud-Levi AC, Blesch A, et al. Progress and prospects: gene therapy clinical trials (part 2). Gene Ther. 2007; 14: 1555-1563.
9. Alexander BL, Ali RR, Alton EW, et al. Progress and prospects: gene therapy clinical trials (part 1). Gene Ther. 2007; 14: 1439-1447.
10. During MJ, Xu R, Young D, et al. Peroral gene therapy of lactose intolerance using an adeno-associated virus vector. Nat Med. 1998; 4: 1131-1135. (Pubitemid 28468825)
11. Polyak S, Mah C, Porvasnik S, et al. Gene delivery to intestinal epithelial cells in vitro and in vivo with recombinant adeno-associated virus types 1, 2 and 5. Dig Dis Sci. 2008; 53: 1261-1270. (Pubitemid 351514644)
12. Boutin S, Monteilhet V, Veron P, et al. Prevalence of serum IgG and neutralizing factors against adeno-associated virus (AAV) types 1, 2, 5, 6, 8, and 9 in the healthy population: implications for gene therapy using AAV vectors. Hum Gene Ther. 2010; 21: 704-712.
13. Calcedo R, Vandenberghe LH, Gao G, et al. Worldwide epidemiology of neutralizing antibodies to adeno-associated viruses. J Infect Dis. 2009; 199: 381-390.
14. Halbert CL, Miller AD, McNamara S, et al. Prevalence of neutralizing antibodies against adeno-associated virus (AAV) types 2, 5, and 6 in cystic fibrosis and normal populations: Implications for gene therapy using AAV vectors. Hum Gene Ther. 2006; 17: 440-447.
15. Lin J, Calcedo R, Vandenberghe LH, et al. Impact of preexisting vector immunity on the efficacy of adeno-associated virus-based HIV-1 Gag vaccines. Hum Gene Ther. 2008; 19: 663-669. (Pubitemid 352009917)
16. Petry H, Brooks A, Orme A, et al. Effect of viral dose on neutralizing antibody response and transgene expression after AAV1 vector re-administration in mice. Gene Ther. 2008; 15: 54-60. (Pubitemid 350269433)
17. Stevens R, Oliver M, Brogan M, et al. Defective generation of tetanus-specific antibody-producing B cells after in vivo immunization of Crohn's disease and ulcerative colitis patients. Gastroenterology. 1985; 88: 1860-1866. (Pubitemid 15052298)
18. Negrete A, Kotin RM,. Strategies for manufacturing recombinant adeno-associated virus vectors for gene therapy applications exploiting baculovirus technology. Brief Funct Genomic Proteomic. 2008; 7: 303-311.
19. Polito JM, Childs B, Mellits ED, et al. Crohn's disease: influence of age at diagnosis on site and clinical type of disease. Gastroenterology. 1996; 111: 580-586. (Pubitemid 26293220)
20. Haug K, Schrumpf E, Barstad S, et al. Epidemiology of ulcerative colitis in western Norway. Scand J Gastroenterol. 1988; 23: 517-522.
21. Haug K, Schrumpf E, Halvorsen JF, et al. Epidemiology of Crohn's disease in western Norway. Study group of Inflammatory Bowel Disease in Western Norway. Scand J Gastroenterol. 1989; 24: 1271-1275.
22. Kim JJ, Simpson N, Klipfel N, et al. Cytomegalovirus infection in patients with active inflammatory bowel disease. Dig Dis Sci. 2010; 55: 1059-1065.
23. Kou T, Nakase H, Tamaki H, et al. Cytomegalovirus infection in patients with ulcerative colitis diagnosed by quantitative real-time PCR analysis. Dig Dis Sci. 2006; 51: 1052-1055. (Pubitemid 44127052)
24. Yoshino T, Nakase H, Ueno S, et al. Usefulness of quantitative real-time PCR assay for early detection of cytomegalovirus infection in patients with ulcerative colitis refractory to immunosuppressive therapies. Inflamm Bowel Dis. 2007; 13: 1516-1521.
25. Mueller C, Flotte TR,. Clinical gene therapy using recombinant adeno-associated virus vectors. Gene Ther. 2008; 15: 858-863. (Pubitemid 351712619)
26. Flotte TR,. Gene therapy: the first two decades and the current state-of-the-art. J Cell Physiol. 2007; 213: 301-305. (Pubitemid 47509706)
27. Kotin RM,. Prospects for the use of adeno-associated virus as a vector for human gene therapy. Hum Gene Ther. 1994; 5: 793-801. (Pubitemid 24310566)
28. Sandborn WJ,. Current directions in IBD therapy: what goals are feasible with biological modifiers? Gastroenterology. 2008; 135: 1442-1447.
29. Glocker EO, Kotlarz D, Boztug K, et al. Inflammatory bowel disease and mutations affecting the interleukin-10 receptor. N Engl J Med. 2009; 361: 2033-2045.
30. Kaser A, Zeissig S, Blumberg RS,. Inflammatory bowel disease. Annu Rev Immunol. 2010; 28: 573-621.
31. MacDermott RP,. Chemokines in the inflammatory bowel diseases. J Clin Immunol. 1999; 19: 266-272. (Pubitemid 29489391)
32. MacDermott RP, Sanderson IR, Reinecker HC,. The central role of chemokines (chemotactic cytokines) in the immunopathogenesis of ulcerative colitis and Crohn's disease. Inflamm Bowel Dis. 1998; 4: 54-67. (Pubitemid 128699837)
33. Fedorak RN, Gangl A, Elson CO, et al. Recombinant human interleukin 10 in the treatment of patients with mild to moderately active Crohn's disease. The Interleukin 10 Inflammatory Bowel Disease Cooperative Study Group. Gastroenterology. 2000; 119: 1473-1482. (Pubitemid 32198672)
34. Schreiber S, Fedorak RN, Nielsen OH, et al. Safety and efficacy of recombinant human interleukin 10 in chronic active Crohn's disease. Crohn's Disease IL-10 Cooperative Study Group. Gastroenterology. 2000; 119: 1461-1472. (Pubitemid 32198671)